RxDoctor Payments Data

Chris West, DO

Family Medicine · Parker, CONPI 1265491112

Payments from drug & device makers

$7,587in general payments, 2019–2025

Across 469 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$889
  • Novo Nordisk$655
  • Amgen$537
  • Pfizer$482
  • Lilly USA, LLC$473
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$7,47499%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,587 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.

See all family medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$228,239
Medicare patients
347
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$25,206
EliquisApixaban13$19,661
Testosterone12$1,943
Rosuvastatin Calcium221$1,639
Omeprazole57$1,556
Ezetimibe36$1,209
Nebivolol Hcl12$1,041
ProgesteroneProgesterone, Micronized23$950
Levothyroxine Sodium99$936
Zolpidem Tartrate61$872
Tamsulosin Hcl61$790
Liothyronine Sodium25$771
Atorvastatin Calcium97$737
Duloxetine Hcl28$730
Gabapentin21$652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$473$25,20624 claims
PfizerEliquis$482$19,66113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.

Other family medicine in Parker

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →